GDC-0994 Hydrochloride, also known as Ravoxertinib hydrochloride, is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a potent and selective inhibitor of ERK1/2, which are key components of the MAPK/ERK pathway. This pathway is often dysregulated in various cancers, leading to uncontrolled cell proliferation and survival. The compound is being investigated in clinical trials for its potential to treat solid tumors, particularly those with mutations in the MAPK pathway, such as melanoma, colorectal cancer, and non-small cell lung cancer. By inhibiting ERK1/2, GDC-0994 Hydrochloride aims to halt the growth of cancer cells and induce apoptosis, offering a promising therapeutic approach for patients with limited treatment options. Additionally, its specificity for ERK1/2 makes it a valuable tool in cancer research, aiding in the understanding of the role of this pathway in tumorigenesis and resistance to other targeted therapies. Its development underscores the ongoing efforts to create more effective and precise treatments for cancer patients.